Portfolio Companies

Curacell develops cell based immunotherapies for cancer treatment focusing on TILs (Tumor Infiltrating Lymphocytes), an investigational therapy aimed at a durable cure for solid tumor cancers.

The company is initiating its first clinical program targeting indications with high prevalence and the potential to make a significant impact on cancer patients worldwide.



StromaBio is a clinical stage biopharma company building on more than two decades of research on mesenchymal stromal cells (MSC).

The company has a broad pipeline based on its own product application and is a leader in the field of neurology and acute inflammatory diseases. 


Cellavos develops innovative treatments for horses based on mesenchymal stromal cells (MSC) for a range of chronic diseases.

Cellavos has treated more than 300 horses in pre-clinical studies and is developing clinical programs based on both MSCs from donor horses and extracellular vesicles (EV).